Libya
Tuberculosis profile
Population  2013 6.2 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.54 (0.33–0.82) 8.7 (5.2–13)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 4.4 (2–7.6) 70 (32–123)
Incidence  (includes HIV+TB) 2.5 (2–3) 40 (33–48)
Incidence (HIV+TB only)        
Case detection, all forms (%) 54 (45–66)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 3.7 (2.5–4.9) 20 (13–27)
MDR-TB cases among notified pulmonary
TB cases
33 (22–43) 16 (10–21)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 641   9
Pulmonary, clinically diagnosed 245   0
Extrapulmonary 449   0
       
Total new and relapse 1 344    
Previously treated, excluding relapses 68    
Total cases notified 1 412    
Among 1 344 new and relapse cases:
72 (5%) cases aged under 15 years; male:female ratio: 1.7
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB      
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment      
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 335 (95)
HIV-positive TB patients 52 (4)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)    
HIV-positive TB patients on antiretroviral therapy (ART)    
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 60
Previously treated cases, excluding relapse, registered in 2012 27
HIV-positive TB cases, all types, registered in 2012 34
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 16.0
Drug susceptibility testing (per 5 million population) 1.6
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? No
Financing TB control 2014  
National TB programme budget (US$ millions) 2.1
% Funded domestically 100%
% Funded internationally  
% Unfunded 0%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-08-04 Data: www.who.int/tb/data